Total submissions: 1
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Pittsburgh Clinical Genomics Laboratory, |
RCV004784979 | SCV005397284 | uncertain significance | Cardiac anomalies - developmental delay - facial dysmorphism syndrome | 2021-08-03 | criteria provided, single submitter | clinical testing | This sequence variant is a single nucleotide substitution (C>T) which results in a serine to leucine amino acid change at residue 664 of the MED13L protein. This variant has not been previously reported in medical genetics databases or literature in individuals with MED13L-related disease, to our knowledge. This variant is rare in the gnomAD control population dataset (2/249920 alleles, 0.0008%). Ser664 occurs near a LXXLL receptor-binding motif at amino acid residues 669-673 (Uniprot). Multiple bioinformatic tools predict that this serine to leucine amino acid change is likely to be tolerated, and the Ser664 residue is moderately conserved in mammals. At this time, there is insufficient evidence to determine if this variant is pathogenic or benign. Therefore, we consider it to be a variant of uncertain significance. ACMG Criteria: BP4, PM2 |